IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals In...
March 01 2019 - 5:02PM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces the filing of a class action lawsuit against Vanda
Pharmaceuticals Inc. (“Vanda” or “the Company”) (NASDAQ: VNDA) for
violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities
and Exchange Commission.
Investors who purchased the Company's shares between November 4,
2015 and February 11, 2019, inclusive (the ''Class Period''), are
encouraged to contact the firm before April 26, 2019.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the Complaint, the Company made false and
misleading statements to the market. Vanda engaged in a fraudulent
off-label usage scheme with its drugs Fanapt and Hetlioz. The
Company abused Medicare, Medicaid, and Tricare programs to receive
drug reimbursements from the government. Due to this fraudulent
activity, the Company faced legal action by the government. Based
on these facts, the Company’s public statements were false and
materially misleading throughout the class period. When the market
learned the truth about Vanda, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190301005567/en/
The Schall Law FirmBrian Schall, Esq.,Sherin Mahdavian,
Esq.,www.schallfirm.comOffice: 310-301-3335Cell:
424-303-1964info@schallfirm.com
Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Sep 2023 to Sep 2024